Insulet Co. (NASDAQ:PODD) Stake Increased by Bokf Na

Bokf Na increased its stake in Insulet Co. (NASDAQ:PODD) by 10.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,703 shares of the medical instruments supplier’s stock after buying an additional 1,001 shares during the period. Bokf Na’s holdings in Insulet were worth $2,160,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Private Advisor Group LLC increased its stake in Insulet by 41.8% during the fourth quarter. Private Advisor Group LLC now owns 2,121 shares of the medical instruments supplier’s stock valued at $460,000 after purchasing an additional 625 shares during the last quarter. Principal Securities Inc. bought a new stake in Insulet during the fourth quarter valued at $69,000. Dimensional Fund Advisors LP increased its stake in Insulet by 0.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 124,280 shares of the medical instruments supplier’s stock valued at $26,968,000 after purchasing an additional 834 shares during the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in Insulet by 14.0% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,340 shares of the medical instruments supplier’s stock valued at $508,000 after purchasing an additional 287 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its stake in Insulet by 15.1% during the fourth quarter. Janney Montgomery Scott LLC now owns 7,487 shares of the medical instruments supplier’s stock valued at $1,624,000 after purchasing an additional 982 shares during the last quarter.

Insulet Stock Performance

PODD stock opened at $233.87 on Friday. The company has a market capitalization of $16.40 billion, a P/E ratio of 70.87, a PEG ratio of 4.26 and a beta of 1.21. The company has a 50-day simple moving average of $199.23 and a 200 day simple moving average of $185.86. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $234.71. The company has a quick ratio of 2.71, a current ratio of 3.60 and a debt-to-equity ratio of 1.36.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The business had revenue of $488.50 million during the quarter, compared to analyst estimates of $488.00 million. During the same period in the previous year, the company posted $0.38 earnings per share. Insulet’s revenue was up 23.2% compared to the same quarter last year. Sell-side analysts predict that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PODD has been the subject of several recent research reports. UBS Group boosted their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research note on Friday, August 9th. Barclays boosted their price target on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. OTR Global reissued a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Redburn Atlantic assumed coverage on shares of Insulet in a report on Thursday, May 30th. They set a “buy” rating and a $235.00 price target for the company. Finally, BTIG Research reduced their price target on shares of Insulet from $270.00 to $250.00 and set a “buy” rating for the company in a report on Friday, August 9th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $225.29.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.